key: cord-1035089-y7j3k9xn
authors: Hall, Peter A.; Meng, Gang; Hudson, Anna; Sakib, Mohammad N.; Hitchman, Sara C.; McKillop, James; Bickel, Warren K.; Fong, Geoffrey T.
title: Cognitive dysfunction following SARS-CoV-2 infection in a population-representative Canadian sample: A cross sectional study
date: 2022-03-21
journal: Brain Behav Immun Health
DOI: 10.1016/j.bbih.2022.100454
sha: 480139f531f9027b57a35bcb88ae93c22f6300ac
doc_id: 1035089
cord_uid: y7j3k9xn

BACKGROUND: Prior studies have documented reliable associations between SARS-CoV-2 infection and adverse cognitive impact, at least in older adults. The current study sought to determine whether SARS-CoV-2 infection and COVID-19 symptom severity are associated with cognitive dysfunction among young and middled-aged adults in the general population. METHOD: The Canadian COVID-19 Experiences Project (CCEP) survey involves 1958 adults with equal representation of vaccinated and vaccine hesitant adults between the ages of 18 and 54 years. The sample comprised 1958 adults with a mean age of 37 years (SD = 10.4); 60.8% were female. The primary outcome was symptoms of cognitive dysfunction assessed via an abbreviated form of the Barkley Deficits in Executive Functioning Scale (BDEFS) and performance on a validated delay-discounting task. RESULTS: Young and middle-aged adults with a positive SARS-CoV-2 infection history reported a significantly higher number of symptoms of executive dysfunction (M(adj) = 1.89, SE = 0.08, CI: 1.74, 2.04; n = 175) than their non-infected counterparts (M(adj) = 1.63, SE = 0.08, CI: 1.47,1.80; n = 1599; β = 0.26, p = .001). Among those infected, there was a dose-response relationship between COVID-19 symptom severity and level of executive dysfunction, with moderate (β = 0.23, CI: 0.003–0.46) and very/extremely severe (β = 0.69, CI: 0.22–1.16) COVID-19 symptoms being associated with significantly greater dysfunction, compared to asymptomatic. These effects remained reliable and of similar magnitude after controlling for demographics, vaccination status, mitigation behavior frequency, and geographic region, and after removal of those who had been intubated during hospitalization. Very similar—and comparatively stronger—effects were found for the delay-discounting task, and when using only PCR confirmed SARS-CoV-2 cases. CONCLUSIONS: Positive SARS-CoV-2 infection history and COVID-19 symptom severity are associated with executive dysfunction among young and middle-aged adults with no history of medically induced coma. These findings are evident on self-reported and task-related indicators of cognitive function.

dysfunction, compared to asymptomatic. These effects remained reliable and of similar 53 magnitude after controlling for demographics, vaccination status, mitigation behavior 54 frequency, and geographic region, and after removal of those who had been intubated 55 during hospitalization. Very similar-and comparatively stronger-effects were found for 56 the delay-discounting task, and when using only PCR confirmed SARS-CoV-2 cases.

Conclusions: Positive SARS-CoV-2 infection history and COVID-19 symptom severity 59 are associated with executive dysfunction among young and middle-aged adults with no 60 history of medically induced coma. These findings are evident on self-reported and task-61 related indicators of cognitive function.

Cognitive dysfunction is one of the potential adverse consequences of SARS-CoV-2 66 infection, and this risk may extend well below the age margins for increased mortality 67 risk. It is understood that SARS-CoV-2 could impact the brain through a number of non-68 exclusive, indirect mechanisms including hypoxia, thrombosis, coagulopathy, cytokine 69 storm, and megakaryocyte invasion. [1] [2] [3] [4] [5] [6] [7] Studies of predominantly older, hospitalized 70 patients have revealed cognitive deficits in the areas of memory, spatial navigation, 71 attention, short-term memory, and executive function. 6 Executive functions are partially supported by the lateral prefrontal cortex, as well as 87 the medial orbitofrontal cortex (mOFC). The mOFC is of particular interest, being the 88 brain subregion most anatomically close to the hypothesized point of SARS-CoV-2 89 neuroinvasion. Decision-making processes supported by the OFC can be best 90 assessed using decision-making paradigms with heavy temporal and evaluative 91 demands, such as a delay discounting task. 15-18 Delay discounting is a neurobehavioral 92 process reflecting the extent to which future rewards are devalued based on their delay 93 in time 19 and summarized relative balance between the prefrontal cortices and the 94 limbic systems. 15 Greater delay discounting is reflected in the tendency to choose a 95 lower value option that is immediately available over a higher value option that is 96 delayed in time.

Prior studies have shown that damage to the mOFC is associated with increased 98 delay discounting. 17,18 Impulsive choice of rewards is mediated by dopaminergic activity 99 within the mOFC, 20 in contrast with choices to avoid punishment, which are mediated by 100 the lateral OFC. 21 The most anterior aspect of the mOFC has further been proposed as revealed prospective reductions OFC grey matter following infection with SARS-CoV-2, 109 among other findings implicating proximity and connectivity to the olfactory bulb. 24 

The current study reports findings from a large national survey of adults in the CoV-2, it was expected that deficits would be evident on a delay discounting task. dose, but were not intending to receive a second. Employing quota sampling enabled 128 an examination of factors that predict caseness with high statistical power, and also 129 ensured that the use of caseness as a control variable was maximally stringent (e.g., 130 controlling for vaccination status when the sample is a 1:1 ratio of vaccinated to 131 unvaccinated). The mean age was 37.0 (SD=10.4) and 60.8% were female. Executive dysfunction. Symptoms of executive dysfunction were assessed using four 148 "self-restraint" subscale items from the Deficits in Executive Functioning Scale, short 149 form (BDEFS-SF). 27 Respondents were asked how often they have experienced each the four problems during the past 6 months, including "I am unable to inhibit my 151 reactions or responses to events or to other people", "I make impulsive comments to 152 others", "I am likely to do things without considering the consequences for doing them", 153 and "I act without thinking". Responses were indicated on a numerical scale where 1= 154 never or rarely, 2=sometimes, 3=often, and 4=very often. Cronbach's alpha for the 4 155 items was 0.89, indicating acceptable reliability. The four executive dysfunction items 156 were averaged for this analysis to create a composite executive dysfunction measure.

Delay discounting. To assess delay discounting, participants competed a validated 5-158 trial delay discounting task wherein they were presented with a series of hypothetical 159 choices between a smaller monetary amount ($500) immediately or a larger amount 160 ($1,000) at various time delays (e.g.,1 month, 3 months). 28 Delay discounting was 

Baseline characteristics of the sample are presented in Table 1 . The majority of the 203 participants were female (60%) and from the 25-39 (40%) or 40-54 (43%) age groups.

84% of participants reported that they had not been infected; those who reported having 205 been infected reported symptoms to be "not at all severe" (3%), "slightly severe" (2.4%), 206 "moderately severe" (2.7%), with relatively few experiencing "very/extremely severe" (Table 2) . (Table   243 3).

In general, males had marginally steeper discount rates than females (β=-.10, It is not clear why there appeared to be a stronger link between SARS-CoV-2 321 infection and cognitive dysfunction in younger adults as compared with middle-aged 322 adults. It is possible that such deficits were more salient to younger adults, given that a 323 higher proportion would be in educational programs wherein lapses in attention and 324 concentration may have been more impactful. It is noteworthy that there was no 325 evidence of age moderation on the corresponding task-related cognitive indicator, which 326 may support the hypothesis that the age effect is a reporting bias rather than reflective 327 of a stronger pathophysiological process among younger adults as compared to middle-328 aged adults. Future studies using other datasets should examine the extent to which the dose-370 response and age gradients observed here are replicable across samples. Finally, 371 additional studies examining neurological impacts at the level of the brain itself will be 372 required, using brain imaging paradigms to quantify structural and functional impacts of as "not at all severe". The adjusted parameters are adjusted by sex and group. Table 1 430 includes the sample used in the current analysis (N = 1,902). PH, GF, and SH conceived the study, planned and oversaw the statistical analyses, and 

How COVID-19 Affects the Brain

Neurologic Manifestations of Hospitalized Patients 458

With Coronavirus Disease

The Emerging Threat of (Micro)Thrombosis in

COVID-19 and Its Therapeutic Implications

Assessing Brain Capillaries in 464

Neurological consequences 467 of COVID-19 and brain related pathogenic mechanisms: A new challenge for 468 neuroscience

The emergence of cognitive COVID

Neurological infection with SARS-CoV-2 -the story so far

Frequency and profile of objective cognitive deficits in hospitalized patients 476 recovering from COVID-19

Persistent symptoms after Covid-19: 479 qualitative study of 114 "long Covid" patients and draft quality principles for 480 services

As Their Numbers Grow, COVID-19 "Long Haulers

Assessment of Cognitive Function in 485

Patients After COVID-19 Infection

Post-infection cognitive impairments in a cohort 488 of elderly patients with COVID-19

COVID-19 infection: Clinical predictors leading to neuropsychological impairment

Cognitive Deficits in People Who 494

Have Recovered from COVID-19 Relative to Controls: An N=84,285 Online Study

Value Immediate and Delayed Monetary Rewards

Separate and 500 overlapping brain areas encode subjective value during delay and effort 501 discounting

Myopic Discounting of Future Rewards 507 after Medial Orbitofrontal Damage in Humans

Toward a behavioral economic understanding of drug 510 dependence: delay discounting processes

Prefrontal and Orbitofrontal Cortex during a Test of Impulsive Choice

The functional neuroanatomy of the human orbitofrontal 517 cortex: evidence from neuroimaging and neuropsychology

Findings in COVID-19 Patients. The Laryngoscope

6-month neurological 523 and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort 524 study using electronic health records

SARS-CoV-2 is associated with 528 changes in brain structure in UK Biobank

The Canadian COVID-19 Experiences Survey: Study 530 Protocol

COVID-19 daily epidemiology update. aem

Barkley Deficits in Executive Functioning Scale (BDEFS)

A 5-trial adjusting delay discounting task: Accurate 539 discount rates in less than one minute

The symptom perception hypothesis revised: Depression and 542 anxiety play different roles in concurrent and retrospective physical symptom 543 reporting

Associations between a one-shot 545 delay discounting measure and age, income, education and real-world impulsive 546 behavior

Suicidal Ideation During the COVID-19 Pandemic -United States

Impact of COVID-19 pandemic on mental health 553 in the general population: A systematic review

An investigation of mental health status of children 556 and adolescents in china during the outbreak of COVID-19

Longitudinal changes in mental health and the 559 COVID-19 pandemic: evidence from the UK Household Longitudinal Study

Biobehavioral Aspects of the COVID-19 563 Pandemic: A Review

Infection in Children and Adults: Results of a National British Surveillance Study

Neurological Complications during Treatment of 569

Middle East Respiratory Syndrome

preliminary 573 report of a case-control study

Neurological Complications of Herpes Simplex Virus Type 2 576 Infection

Neurologic Complications of the Reactivation of Varicella-Zoster Virus

Covid-19: Early studies give hope omicron is milder than other variants

Decreased severity of disease during the first 583 global omicron variant covid-19 outbreak in a large hospital in tshwane, south 584 africa

Severity of Omicron 587 variant of concern and vaccine effectiveness against symptomatic disease: national 588 cohort with nested test negative design study in Scotland

The authors declare no conflicts of interest.J o u r n a l P r e -p r o o f